TABLE 2.
Clinical trials of IDH, HDAC, SAM cycle and others.
| Category | Drugs | NCT number | Title | Condition | Status | Phase |
|---|---|---|---|---|---|---|
| IDH inhibitors | Enasidenib | NCT02677922 | A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) | Active, not recruiting | Leukemia, Myeloid, Acute | Phase 1/Phase 2 |
| Enasidenib | NCT01915498 | Phase 1/2 Study of Enasidenib (AG-221) in Adults with Advanced Hematologic Malignancies with an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation | Active, not recruiting | Hematologic Neoplasms | Phase 1/Phase 2 | |
| AG881 | NCT02481154 | Study of Orally Administered AG-881 in Patients with Advanced Solid Tumors, Including Gliomas, with an IDH1 and/or IDH2 Mutation | Active, not recruiting | Glioma | Phase 1 | |
| HDAC inhibitors | Romidepsin | NCT00426764 | A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma | Completed | Peripheral T-cell Lymphoma | Phase 2 |
| Romidepsin | NCT00106431 | A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) | Completed | Cutaneous T-cell Lymphoma | Phase 2 | |
| Vorinostat | NCT01266031 | Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults with Recurrent Glioblastoma | Completed | Recurrent Glioblastoma | Phase 1/Phase 2 | |
| SAM cycle inhibitors | Ethylornithine | NCT01483144 | Trial of Eflornithine Plus Sulindac in Patients with Familial Adenomatous Polyposis (FAP) | Completed | Familial Adenomatous Polyposis | Phase 3 |
| Ethylornithine | NCT00033371 | Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients with Familial Adenomatous Polyposis | Completed | Colorectal Cancer, Familial Adenomatous Polyposis | Phase 2 | |
| Ethylornithine | NCT01059071 | Safety Study for Refractory or Relapsed Neuroblastoma with DFMO Alone and in Combination with Etoposide | Completed | Neuroblastoma | Phase 1 | |
| Others | Physical activity and dietary change | NCT00811824 | Effects of Physical Activity and Dietary Change in Minority Breast Cancer Survivors | Completed | Breast Cancer | Phase 2 |
| Vitamin C | NCT02877277 | Epigenetics, Vitamin C and Abnormal Hematopoiesis - Pilot Study | Completed | Myelodysplastic Syndrome, Acute Myeloid Leukemia | Not Applicable |